SGTXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (11 8月 2023 @ 05:00):

Stats
本日の出来高	81 878.00
平均出来高	120 683
時価総額	56.22M
EPS	$0 ( 2024-03-12 )
次の収益日	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.515
ATR14	$1.161 (5.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-11	Flagship Ventures Fund V General Partner Llc	Sell	113 960	Common Stock
2023-08-11	Eli Lilly & Co	Buy	1 718 493	Common Stock
2023-08-11	Cole Douglas G.	Sell	683	Stock Option (Right to Buy)
2023-08-11	Cole Douglas G.	Sell	683	Stock Option (Right to Buy)
2023-08-11	Oesterle Stephen N.	Sell	683	Stock Option (Right to Buy)

INSIDER POWER
68.76
Last 96 transactions
Buy: 15 034 169 \| Sell: 5 311 777

ボリューム相関

長: 0.16 (neutral)

短: 0.00 (neutral)

Signal:(71.261) Neutral

Sigilon Therapeutics, 相関

10 最も正の相関
OCUL	0.908
ICAD	0.899
MORF	0.885
SVC	0.88
RBBN	0.879
MHUA	0.877
SJ	0.876
MSSA	0.874
VRCA	0.872
USAP	0.868

10 最も負の相関
RGF	-0.902
GSMG	-0.889
ACRX	-0.877
JRJC	-0.868
ESSA	-0.865
IBRX	-0.864
ALLK	-0.86
APEI	-0.859
FLIC	-0.858
BNIXU	-0.857

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Sigilon Therapeutics, 相関 - 通貨/商品

0.25
( neutral )

0.67
( moderate )

0.52
( weak )

0.48
( neutral )

-0.84
( strong negative )

-0.24
( neutral )

Sigilon Therapeutics, 財務諸表

Annual	2022
収益:	$12.94M
総利益:	$12.94M (100.00 %)
EPS:	$-1.340

FY	2022
収益:	$12.94M
総利益:	$12.94M (100.00 %)
EPS:	$-1.340

FY	2021
収益:	$9.60M
総利益:	$0.00 (0.00 %)
EPS:	$-2.43

FY	2020
収益:	$13.37M
総利益:	$13 374.00 (0.10 %)
EPS:	$-7.55

Financial Reports:

No articles found.

Sigilon Therapeutics,

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.